visceral adipose tissue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
This is a timeline of the main events of the Cold War, a state of political and military tension after World War II between powers in the Western Bloc (the United States, its NATO allies, South Vietnam, South Korea, and others) and powers in the Eastern Bloc (the Soviet Union, its allies in the Warsaw Pact, China, Cuba, North Vietnam and North Korea).
Prior to any physical examination, the diagnosis of keratoconus frequently begins with an ophthalmologist's or optometrist's assessment of the person's medical history, particularly the chief complaint and other visual symptoms, the presence of any history of ocular disease or injury that might affect vision, and the presence of any family history of ocular disease. An eye chart, such as a standard Snellen chart of progressively smaller letters, is then used to determine the person's visual acuity. The eye examination may proceed to measurement of the localized curvature of the cornea with a manual keratometer, with detection of irregular astigmatism suggesting a possibility of keratoconus. Severe cases can exceed the instrument's measuring ability. A further indication can be provided by retinoscopy, in which a light beam is focused on the person's retina and the reflection, or reflex, observed as the examiner tilts the light source back and forth. Keratoconus is amongst the ophthalmic conditions that exhibit a scissor reflex action of two bands moving toward and away from each other like the blades of a pair of scissors. If keratoconus is suspected, the ophthalmologist or optometrist will search for other characteristic findings of the disease by means of slit lamp examination of the cornea. An advanced case is usually readily apparent to the examiner, and can provide for an unambiguous diagnosis prior to more specialized testing.
=== Pharmacodynamics === Oxa-noribogaine acts as an atypical κ-opioid receptor (KOR) partial agonist similarly to noribogaine but shows dramatically increased potency and selectivity compared to noribogaine (EC50Tooltip half-maximal effective concentration = 43 nM vs. 6,100 nM, respectively; 142-fold difference). It produces analgesic effects in animals, but unlike conventional KOR agonists, does not produce aversive or pro-depressive effects. The drug induces a robust KOR-dependent increase in GDNF levels in the ventral tegmental area (VTA) and medial prefrontal cortex (mPFC). After a single dose or short-term treatment, oxa-noribogaine induces long-lasting suppression of opioid drug-seeking behavior in rodent relapse models. It also counteracts persistent opioid-induced hyperalgesia. In addition, oxa-noribogaine decreases alcohol consumption in rodents.
== Evolution == The opioid receptor (OR) family originated from two duplication events of a single ancestral opioid receptor early in vertebrate evolution. Phylogenetic analysis demonstrates that the family of opioid receptors was already present at the origin of jawed vertebrates over 450 million years ago. In humans, this paralogon resulting from a double tetraploidization event resulted in the receptor genes being located on chromosomes 1, 6, 8, and 20. Tetraploidization events often result in the loss of one or more of the duplicated genes, but in this case, nearly all species retain all four opioid receptors, indicating biological significance of these systems. Stefano traced the co-evolution of OR and the immune system underlying the fact that these receptors helped earlier animals to survive pain and inflammation shock in aggressive environments. The receptor families delta, kappa, and mu demonstrate 55–58% identity to one another, and a 48–49% homology to the nociceptin receptor. Taken together, this indicates that the NOP receptor gene, OPRL1, has equal evolutionary origin, but a higher mutation rate, than the other receptor genes. Although opioid receptor families share many similarities, their structural differences lead to functional difference. Thus, mu-opioid receptors induce relaxation, trust, satisfaction, and analgesia. This system may also help mediate stable, emotionally committed relationships. Experiments with juvenile guinea pigs showed that social attachment is mediated by the opioid system.
Dinosterol has been used as an indicator for dinoflagellate production in the Cariaco Basin. In such studies, it has been revealed that the accumulation of dinosterol peaks at a rate of almost 900 mg compound/cm2/yr during the Younger Dryas. Hydrogen isotope ratios in dinosterols can serve to reconstruct salinity semi-quantitatively. Some studies have revealed that certain dinoflagellates produce sterols that have the potential to serve as genera-specific biomarkers. Recent work showed that dinoflagellate genera, which formed discrete clusters in the 18S rDNA-based phylogeny, shared similar sterol compositions. This suggested that the sterol compositions of dinoflagellates are explained by the evolutionary history of this lineage.
Sources: en.wikipedia.org
== Food industry == In the food industry, aminopeptidases from Aspergillus oryzae and Aspergillus sojae are utilized for debittering protein hydrolysates, including those used in soy sauce and miso production. These enzymes help remove bitter-tasting peptides, enhancing the flavor and palatability of these products. Aminopeptidases also play a crucial role in cheese ripening by participating in the proteolysis of milk proteins. This enzymatic action contributes significantly to the development of the cheese's flavor and texture, making aminopeptidases essential in the cheese-making process. When aminopeptidases are used in food processing, it is crucial to ensure that they are food-grade and safe for consumption. Aminopeptidases from A. oryzae and A. sojae, for example, have been extensively studied and are considered safe for use in food applications. It is important to handle these enzymes under conditions that prevent contamination and degradation, which could affect both the safety and quality of the food products. Aminopeptidases require specific storage conditions to maintain their stability and enzymatic activity. For instance, human aminopeptidase A is stable at a pH range of 7.0–8.5 and can be stored at −20 °C for several months without significant loss of activity. Similarly, a halotolerant intracellular protease from Bacillus subtilis strain FP-133, which exhibits aminopeptidase activity, retains full activity after being stored in 7.5% (w/v) NaCl at 4 °C for 24 hours.
Therefore, while the electronic placement of hydrogen in group 1 predominates, some rarer arrangements show either hydrogen in group 17, duplicate hydrogen in both groups 1 and 17, or float it separately from all groups. This last option has nonetheless been criticized by the chemist and philosopher of science Eric Scerri on the grounds that it appears to imply that hydrogen is above the periodic law altogether, unlike all the other elements. Helium is the only element that routinely occupies a position in the periodic table that is not consistent with its electronic structure. It has two electrons in its outermost shell, whereas the other noble gases have eight; and it is an s-block element, whereas all other noble gases are p-block elements. However it is unreactive at standard conditions, and has a full outer shell: these properties are like the noble gases in group 18, but not at all like the reactive alkaline earth metals of group 2. For these reasons helium is nearly universally placed in group 18 which its properties best match; a proposal to move helium to group 2 was rejected by IUPAC in 1988 for these reasons. Nonetheless, helium is still occasionally placed in group 2 today, and some of its physical and chemical properties are closer to the group 2 elements and support the electronic placement. Solid helium crystallises in a hexagonal close-packed structure, which matches beryllium and magnesium in group 2, but not the other noble gases in group 18.
== Etymology and names == The names "scallion" and "shallot" are derived from the Old French eschalotte, by way of eschaloigne, from the Latin Ascalōnia caepa or Ascalonian onion, a namesake of the ancient city of Ascalon. The term "shallot" is usually applied to the French red shallot (Allium cepa var. aggregatum, or the A. cepa aggregatum group). It is also used for the Persian shallot or musir (A. stipitatum) from the Zagros Mountains in Iran and Iraq, and the French gray shallot (Allium oschaninii), which is also known as griselle or "true shallot"; it grows wild from Central to Southwest Asia. The name shallot is also used for a scallion in New South Wales, Australia and among English-speaking people in Quebec, while the term "French shallot" refers to the plant referred to on this page. In most English-speaking nations, the name is pronounced with the emphasis on the last syllable in common with the French pronunciation, sha-LOT, while the emphasis is commonly made on the first syllable, SHAL-ət, in the United States. The term "eschalot", derived from the French word échalote, can also be used to refer to the shallot.
=== Negative === When insulin binds to the cell's receptor, it results in negative feedback by limiting or stopping some other actions in the cell. It inhibits the release and production of glucose from the cells which is an important part in reducing the glucose blood level. Insulin will also inhibit the breakdown of glycogen into glucose by inhibiting the expression of the enzymes that catalyzes the degradation of glycogen. An example of negative feedback is slowing or stopping the intake of glucose after the pathway was activated. Negative feedback is shown in the insulin signal transduction pathway by constricting the phosphorylation of the insulin-stimulated tyrosine. The enzyme that deactivates or phosphorylates the insulin-stimulated tyrosine is called tyrosine phosphatases (PTPases). When activated, this enzyme provides a negative feedback by catalyzing the dephosphorylation of the insulin receptors. The dephosphorylation of the insulin receptor slows down glucose intake by inhibiting the activation (phosphorylation) of proteins responsible for further steps of the insulin transduction pathway.
Noted for his longevity in the game, Fletcher played a total of 400 senior VFL/AFL games, which stands as the fifth-highest number of games by any player as of 2023. His AFL career length of 22 years and 58 days is an all-time league record (edging out Vic Cumberland, whose former record was five days shy of 22 years). Fletcher played his 400th game in Round 9, 2015, becoming the third player in VFL/AFL history to reach the milestone (after Michael Tuck and Kevin Bartlett); it would end up being his final game, as he was unable to recover from a groin injury sustained during the match. He holds the outright Essendon games record, having overtaken the previous record of 378 games held by Simon Madden in Round 1, 2014. He is the second-oldest player to play a VFL/AFL game, aged 40 years and 23 days at the time of his final game, behind only the aforementioned Vic Cumberland (who played the 1920 season at the age of 43). With his father, Ken, the Fletchers hold the record for the most VFL/AFL career games played by a father and son, with 664 games between them. On 12 January 2016, during the summer after his retirement, Fletcher was named as one of 34 past and present Essendon players found guilty over their use of illegal supplements during the 2012 AFL season. As a result, Fletcher was suspended from playing at all levels for 24 months, which with backdating and provisional suspension served resulted in suspension until November 2016. However, Fletcher had already retired the previous year, so the suspension was moot.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.